Clinical trials: Extensive Stage Lung Small Cell Carcinoma
Extensive-Stage Small Cell Lung Cancer
A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer
This is a phase I, open-label, multi-center, non-randomized, 2-part first time inhuman (FTIH) study for SYHA1807. Part 1 is a dose escalation phase to determine the recommended phase 2 dose (RP2D) for SYHA1807 based on the…
- Trial name
- NCT04404543
- Testing
- SYHA1807
- Volunteers
- 71 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma (SCLC)
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1)…
- Trial name
- DAREONᵀᴹ-8 (NCT06077500)
- Testing
- BI 764532, Carboplatin, Etoposide
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Extensive-stage Small-cell Lung Cancer
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with…
- Trial name
- NCT04902885
- Testing
- Trilaciclib, carboplatin, etoposide，or Topotecan
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Extensive-Stage Small Cell Lung Cancer
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
This is an open-label, multi-center Phase II study designed to evaluate the efficacy and safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of care in patients with ES-SCLC.
- Trial name
- NCT05509699
- Testing
- Surufatinib, Anti-PD-1/L1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hutchison Medipharma Limited
Extensive-stage Small-cell Lung Cancer
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT07654400
- Testing
- BL-M14D1, Atezolizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
- Trial name
- MERU (NCT03033511)
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 308 sites in United States, Australia and 39 more
- Volunteers
- 748 people
- Sponsor
- AbbVie
Carcinoma, Small Cell Lung
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have…
- Trial name
- Match (NCT04622228)
- Testing
- Atezolizumab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Extensive-stage Small-cell Lung Cancer
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
- Trial name
- SCLC (NCT04894591)
- Testing
- Zepzelca
- Where
- 41 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Jazz Pharmaceuticals
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 243 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC).
- Trial name
- NCT02735980
- Testing
- Prexasertib
- Where
- 41 sites in United States, France and 8 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Small-cell Lung Cancer
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of…
- Trial name
- NCT03371979
- Testing
- Pegzilarginase, Pembrolizumab
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 42 people
- Sponsor
- Immedica Pharma AB
Small Cell Lung Carcinoma
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with…
- Trial name
- SKYSCRAPER-02C (NCT04665856)
- Testing
- Tiragolumab, Atezolizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Small Cell Lung Cancer (SCLC)
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer…
- Trial name
- NCT07226999
- Testing
- PF-08634404, Atezolizumab, Chemotherapy
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 550 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced…
- Trial name
- NCT02514447
- Testing
- Trilaciclib, Topotecan
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- G1 Therapeutics, Inc.
Lung Cancer
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544674
- Testing
- PR104, F-18-fluoromisonidazole
- Where
- 18 sites in United States
- Volunteers
- 5 people
- Sponsor
- Proacta, Incorporated
Small Cell Lung Cancer
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus…
- Trial name
- NCT00363415
- Testing
- pemetrexed, etoposide, carboplatin
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 908 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.
- Trial name
- NCT03116971
- Testing
- M3814, Cisplatin, Etoposide
- Where
- 80 sites in United States, Belgium and 11 more
- Volunteers
- 2 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Extensive Stage Small Cell Lung Cancer
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
- Trial name
- NCT05468489
- Testing
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Where
- 67 sites in United States
- Volunteers
- 200 people
- Sponsor
- Shanghai Henlius Biotech